Advertisement
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fundamental Analysis

6990.HKHKSE
HealthcareBiotechnology
HK$418.00
HK$5.40(1.31%)
Hong Kong Market opens in 38h 14m
Advertisement

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fundamental Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) shows weak financial fundamentals with a PE ratio of -72.75, profit margin of -20.35%, and ROE of -8.96%. The company generates $0.8B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Current Ratio5.13

Areas of Concern

ROE-8.96%
Operating Margin-16.36%
Cash Position4.68%
PEG Ratio5.69
We analyze 6990.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 7.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
7.1/100

We analyze 6990.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

6990.HK struggles to generate sufficient returns from assets.

ROA > 10%
-2.87%

Valuation Score

Moderate

6990.HK shows balanced valuation metrics.

PE < 25
-72.75
PEG Ratio < 2
5.69

Growth Score

Weak

6990.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

6990.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
5.13

Profitability Score

Weak

6990.HK struggles to sustain strong margins.

ROE > 15%
-895.53%
Net Margin ≥ 15%
-20.35%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is 6990.HK Expensive or Cheap?

P/E Ratio

6990.HK trades at -72.75 times earnings. This suggests potential undervaluation.

-72.75

PEG Ratio

When adjusting for growth, 6990.HK's PEG of 5.69 indicates potential overvaluation.

5.69

Price to Book

The market values Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. at 2.30 times its book value. This may indicate undervaluation.

2.30

EV/EBITDA

Enterprise value stands at -105.41 times EBITDA. This is generally considered low.

-105.41

How Well Does 6990.HK Make Money?

Net Profit Margin

For every $100 in sales, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. keeps $-20.35 as profit after all expenses.

-20.35%

Operating Margin

Core operations generate -16.36 in profit for every $100 in revenue, before interest and taxes.

-16.36%

ROE

Management delivers $-8.96 in profit for every $100 of shareholder equity.

-8.96%

ROA

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. generates $-2.87 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.87%

Following the Money - Real Cash Generation

Operating Cash Flow

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. generates limited operating cash flow of $66.12M, signaling weaker underlying cash strength.

$66.12M

Free Cash Flow

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. generates weak or negative free cash flow of $6.51M, restricting financial flexibility.

$6.51M

FCF Per Share

Each share generates $0.03 in free cash annually.

$0.03

FCF Yield

6990.HK converts 0.05% of its market value into free cash.

0.05%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-72.75

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

5.69

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.30

vs 25 benchmark

P/S Ratio

Price to sales ratio

14.73

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.13

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.09

vs 25 benchmark

ROA

Return on assets percentage

-0.03

vs 25 benchmark

ROCE

Return on capital employed

-0.03

vs 25 benchmark

How 6990.HK Stacks Against Its Sector Peers

Metric6990.HK ValueSector AveragePerformance
P/E Ratio-72.7529.63 Better (Cheaper)
ROE-8.96%223.00% Weak
Net Margin-20.35%-38669.00% (disorted) Weak
Debt/Equity0.020.82 Strong (Low Leverage)
Current Ratio5.134.30 Strong Liquidity
ROA-2.87%-379.00% (disorted) Weak

6990.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ